← Back to Search

Glutamate Receptor Antagonist

Mavoglurant for Alcohol Consumption

Phase 1
Waitlist Available
Led By Suchitra Krishnan-Sarin, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Social drinkers
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 10
Awards & highlights

Study Summary

This trial is testing whether the drug mavoglurant affects how people respond to alcohol, including feeling intoxicated or sedated. 40 people will be given either the drug or a placebo, and the effects will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You consume alcohol regularly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 10
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 10 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Abnormal Labs and Adverse Events

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 200 mg MavoglurantExperimental Treatment1 Intervention
200 mg mavoglurant once daily for 7-10 days
Group II: PlaceboPlacebo Group1 Intervention
Placebo once daily for 7-10 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mavoglurant
2018
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
791 Previous Clinical Trials
1,356,950 Total Patients Enrolled
Yale UniversityLead Sponsor
1,837 Previous Clinical Trials
2,728,379 Total Patients Enrolled
Suchitra Krishnan-Sarin, PhDPrincipal Investigator - Professor of Psychiatry
Yale University
4 Previous Clinical Trials
236 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

May I join the clinical experiment at this time?

"This experiment is searching for 40 social drinkers aged 21-50, who are willing to abstain from alcohol during their outpatient medication treatment period."

Answered by AI

Is eligibility for this experiment restricted to those below a certain age?

"This clinical trial has specified that only those aged 21-50 are eligible for enrollment, in accordance with the established parameters."

Answered by AI

Is it prudent to take Mavoglurant for medical purposes?

"Due to the nature of this Phase 1 trial, which has only minimal data supporting efficacy and safety, Mavoglurant scored a 1 on our team's risk-assessment scale."

Answered by AI

Has any additional research been conducted with regards to the efficacy of Mavoglurant?

"At present, there is one ongoing research trial for Mavoglurant. This study has not yet advanced to Phase 3 and is mainly based in New Haven, Connecticut with a single other location also running trials."

Answered by AI

How many participants have joined this research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical investigation is still searching for participants and began on February 7th 2018. The trial was last modified on April 25th 2022 and 40 volunteers are needed from a single site."

Answered by AI

Are there any available spots in this trial for participants?

"Affirmative, the information available on clinicaltrials.gov affirms that this research is actively enrolling participants. This trial was first submitted to the website on February 7th 2018 and latest modifications were made April 25th 2022. The study requires 40 volunteers at a single medical centre."

Answered by AI
~5 spots leftby Mar 2025